GelMEDIX

GelMEDIX, founded by a world-leading ophthalmologic surgeon at Harvard and bioengineers at UCLA, addresses significant problems in ophthalmology - corneal injuries and complicated ophthalmic drug treatment regimens. The GelMEDIX platform is based on light activated biomaterial with three unique properties: exceptional tissue adhesion, tunable drug elution, and high biocompatibility. The market potential is >>$1b.